摘要
Abstract
Objective To evaluate the efficacy and safety of iron isomaltoside in the treatment of iron deficiency anemia in pa-tients undergoing maintenance hemodialysis(MHD).Methods A retrospective analysis was conducted on 23 MHD patients with iron deficiency anemia.who received intravenous infusion of iron isomaltoside(500 mg per dose,twice in total,with an interval of 1 week),and then were followed up for 6 months.Changes in hemoglobin(Hb),transferrin saturation(TSAT),ferritin(Fer),ad-verse reactions,and changes in the dosage of anemia treatment drugs were observed.Results After treatment,Hb significantly in-creased.At 1 month,the median Hb rose from the baseline of 98.5 g/L to 113.0 g/L,the difference was statistically significant(P<0.05),the median Hb during the peak period(2-5 months)remained at 115.0-117.5 g/L,and was maintained at 115.0g/L at 6 months(P=0.016).TSAT and Fer increased from the baseline of 14.3%and 55.9 μg/L to the peak values of 32.3%(P=0.010)and 436.0 μg/L(P=0.016)(3 months),respectively,it dropped back to 22.3%(P=0.047)and 99.0 μg/L(P=0.031)at 6 months,but was still significantly higher than the baseline,the difference was statistically significant.Only one patient(2%)exhibi-ted a mild allergic reaction.The dosage of ESAs decreased significantly(P=0.012).The overall response Hb rate(Hb≥110g/L)in-creased from 17.4%(4/23)at baseline to 65.2%(15/23)at 6 months(P<0.05).Conclusions Iron isomaltoside can effectively improve iron metabolism and anemia in MHD patients,with favorable safety,which holds clinical promotion value.关键词
异麦芽糖酐铁/贫血/血液透析/血红蛋白/铁蛋白Key words
iron isomaltoside/anemia/hemodialysis/hemoglobin/ferritin分类
医药卫生
